The effectiveness and limitations of some Aglitide for weight loss

Clinical trials show that some Aglitide, the active ingredient in Ozempic and Wegovii, can lead to significant weight loss, with roughly 50% of people losing 10-15% of their body weight and one-third of people losing more than 20%. The trials also demonstrate improvements in blood pressure, cholesterol, and A1C levels, along with potential reductions in heart attacks and strokes. However, real-world studies suggest that the weight loss results may be less pronounced than those seen in the trials. Furthermore, dropout rates in the real world are higher, and weight regain is common once the drug is discontinued. These findings challenge the notion that the drugs will lead to the end of obesity and highlight the importance of considering individual experiences and limitations of the medications.